Exosome Technologies Market

Exosome Technologies Market (Exosome Type: Loaded Cargos [Peptide, siRNA, mRNA, miRNA, Protein, Chemical, and Others] and Non-cargo) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Exosome Technologies Market Outlook 2031

  • The global industry was valued at US$ 47.3 Mn in 2022
  • It is projected to advance at a CAGR of 24.8% from 2023 to 2031 and reach more than US$ 343.5 Mn by 2031

Analysts’ Viewpoint

The global exosome technologies market is expected to witness significant growth in the next few years due to increase in prevalence of cancer and other chronic diseases. Rise in demand for non-invasive diagnostic and therapeutic techniques is also fueling global exosome technologies market development. Furthermore, rise in investment in R&D activities by several governments and increase in adoption of exosome-based products in drug discovery and development are propelling market expansion.

Rise in demand for personalized medicine offers lucrative opportunities for market players. Manufacturers are engaged in developing exosome-based products to increase market share.

However, high cost of exosome-based products and lack of standardization in isolation and purification techniques are expected to restrain market growth in the next few years. Limited awareness about exosome technologies among healthcare professionals and patients is hampering market dynamics.

Exosome Technologies Market

Global Exosome Technologies Market Introduction

Exosomes are small extracellular vesicles that are released by cells and play a crucial role in intercellular communication. These vesicles contain various biomolecules such as proteins, lipids, and nucleic acids, which can be used for diagnostic and therapeutic purposes.

The market includes various products such as isolation kits, characterization kits, and detection kits, which are used for the isolation, purification, and analysis of exosomes. Exosome technologies are used for the diagnosis and treatment of various diseases such as cancer, cardiovascular diseases, and neurological disorders.

Exosomes can be used as biomarkers for disease diagnosis and monitoring, and can also be used as drug-delivery vehicles for targeted therapy. However, one of the major challenges associated with exosome technologies is the heterogeneity of exosomes, which makes their isolation and characterization difficult.

Rise in Prevalence of Chronic Diseases

Chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, are the leading causes of morbidity and mortality across the world. Exosomes, small vesicles secreted by cells, play an important role in cell-to-cell communication and the regulation of several physiological and pathological processes, including the development and progression of chronic diseases.

Exosomes carry several biomolecules, including proteins, nucleic acids, and lipids, which can serve as biomarkers for disease diagnosis and as targets for therapy. The usage of exosomes in the diagnosis and treatment of chronic diseases has been the focus of extensive research in the past few years.

The increase in the prevalence of chronic diseases is driven by several factors, including the aging population, sedentary lifestyles, poor dietary habits, and environmental factors, such as pollution. Globally, around one in three adults suffer from multiple chronic conditions. Six in ten adults in the U.S. have a chronic disease and four in ten adults have two or more.

Exosome-based liquid biopsy has emerged as a promising tool for the non-invasive detection and monitoring of cancer, cardiovascular diseases, and other chronic conditions. Exosomes can also be engineered to deliver therapeutic molecules, such as siRNA, microRNA, and drugs, to target cells, providing a potential new avenue for the treatment of chronic diseases.

Increase in Awareness about the Advantages of Exosome Technologies

Exosomes are gaining popularity within the medical research community, as a type of cell-free therapeutic. Moreover, exosomes play a vital role in several physiological and pathological processes. People are gradually becoming aware of the significant benefits offered by quality diagnostic services when it comes to understanding and treating particular ailments. Manufacturers are increasingly shifting from old to novel development of products to provide effective and rapid diagnosis. This is projected to augment the market in the next few years.

Academic and industrial players are continuously working on enhancing the therapeutic potential of exosomes. Hence, government, public, and private players are taking initiatives to increase funding for research & development. This is fueling market progress. For instance, in December 2020, EVerZom received EUR 1.1 Mn in funding from institutional and private investors to develop its exosome bioproduction platform.

A surge in Demand for Loaded Cargos Owing to its Ability to Carry Various Biomolecules

As per the latest exosome technologies market forecast, the loaded cargos exosome type segment is likely to account for a major share during the forecast period, owing to their ability to carry various biomolecules.

Loaded cargos are exosomes that contain specific molecules or cargo that can be used for therapeutic purposes. These exosomes are important for intercellular communication. The increase in demand for targeted drug delivery systems has led to rising in research activities related to loaded cargo exosomes.

Advancements in technology have enabled researchers to isolate and purify loaded cargo exosomes from different cell sources with high specificity and yield. For instance, in June 2021, Norgen Biotek Corp., a Canada-based biotechnology company specializing in sample preparation products for genomics applications, launched its new product ExoPure, which enables efficient isolation of pure extracellular vesicles including loaded cargo exosomes from various biological fluids.

Several pharmaceutical companies are investing significantly in developing therapeutics based on loaded cargo exosomes due to their potential use as exosome technologies for drug delivery. In August 2020, Evox Therapeutics Ltd., a U.K.-based biotechnology company, announced a collaboration with Eli Lilly and Company for the development of RNA interference (RNAi) therapies using Evox's proprietary platform technology that utilizes engineered exosomal drug payloads.

The ability of MSCs to Secrete High Levels of Exosomes with Therapeutic Potential

Based on cell sources, the MSCs segment dominated the global market in 2022. MSCs are multipotent stem cells that can differentiate into various cell types such as osteoblasts, chondrocytes, and adipocytes. These cells have been found to secrete large amounts of exosomes containing bioactive molecules such as proteins and nucleic acids which can be used for therapeutic purposes.

Several studies have demonstrated the potential use of MSC-derived exosomes in treating various diseases including cardiovascular disorders and neurological disorders. For instance, in May 2021, Codiak BioSciences, Inc. announced positive preclinical data from its lead program exoASO-STAT6, which utilizes MSC-derived exosomes for targeted delivery of antisense oligonucleotides (ASOs) against STAT6 mRNA for the treatment of asthma.

In March 2021, Thermo Fisher Scientific, Inc., launched its new product Exo-FBS, which enables efficient isolation of pure extracellular vesicles including MSC-derived exosomes from fetal bovine serum.

Rise in the Adoption of Exosomes as Diagnostic Markers for Various Diseases

In terms of application, the diagnostics segment accounted for the largest global exosome technologies market share in 2022. Exosomes have been found to contain specific biomolecules such as proteins and nucleic acids that can be used as diagnostic markers for various diseases including cancer, cardiovascular disorders, and neurological disorders. The ability of exosomes to cross biological barriers, such as the blood-brain barrier, has made them attractive targets for developing non-invasive diagnostic tests.

Several companies are investing significantly in developing exosome technologies-based diagnostics biomarkers. For instance, in January 2021, Bio-Techne Corporation announced a collaboration with Vesigen Therapeutics, Inc., a Canada-based biotechnology company focused on developing engineered extracellular vesicles for therapeutic applications for the development of exosome-based liquid biopsy assays.

In November 2020, NanoView Biosciences, Inc. launched its new product ExoView R100 which enables label-free visualization and quantification of individual exosomes from complex biological samples.

Regional Outlook of Global Exosome Technologies Industry

North America is expected to dominate the global market for exosome technologies in the next few years, owing to the presence of major players. As per the latest exosome technologies market report, the U.S. is one of the largest markets for exosome-based products. An increase in the adoption of advanced healthcare technologies coupled with favorable government initiatives has led to a surge in demand for exosome technologies in the region. Furthermore, an increase in funding by private organizations and government bodies toward R&D activities related to cancer diagnosis and treatment using exosomes is fueling the exosome technologies market growth in the region.

Asia Pacific is expected to be the fastest-growing region during the forecast period due to increasing investment by key players in emerging economies such as China and India. These countries have a large patient pool suffering from chronic diseases including cancer which creates exosome technologies market opportunities for companies operating within this space. Additionally, the rise in awareness about personalized medicine among patients along with advancements in biotechnology is contributing to market expansion in this region.

Analysis of Key Players in the Global Exosome Technologies Market

As per the latest exosome technologies market analysis, companies are focusing on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the industry. AEGLE Therapeutics, Aruna Bio, Inc., Bio-Techne Corporation, Carmine Therapeutics, Inc., Codiak BioSciences, Inc., Creative Biolabs, Danaher Corporation (Beckman Coulter, Inc.), Fujifilm Holdings Corporation, NOVADIP Biosciences S.A., OmniSpirant Limited, and Thermo Fisher Scientific, Inc. are the prominent exosome technologies companies operating worldwide.

Key Developments in Global Exosome Technologies Market

  • In October 2022, Aruna Bio, Inc. presented neural exosome treatment opportunities and a lead program, AB126 at Exosome Based Therapeutic Development Summit held in Boston, Massachusetts, the U.S. AB126 is an unmodified neural-derived exosome with the innate ability to cross the blood-brain barrier.
  • In August 2022, Creative Biolabs launched the advanced unique platform i.e., the Nanosight platform for exosome characterization. The Nanosight platform is made accessible to all kinds of research and industrial customers for size distribution analysis, exosome concentration measurement, as well as phenotyping evaluation.
  • In October 2020, AEGLE Therapeutics received the Fast Track designation to AGLE-102 from the U.S. Food and Drug Administration (FDA) for the treatment of patients with dystrophic epidermolysis bullosa (DEB), a rare genetic pediatric skin blistering disorder. AGLE-102 is an extracellular vesicle (EV) therapy that delivers genetic materials, proteins, and regenerative healing factors to diseased and damaged tissue.

Each of these players in the market has been profiled in the exosome technologies industry research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Exosome Technologies Market Snapshot

Attribute

Detail

Size in 2022

US$ 47.3 Mn

Forecast (Value) in 2031

More than US$ 343.5 Mn

Compound Annual Growth Rate (CAGR)

24.8%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Mn for Value

Market Analysis

It includes key segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2022)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Exosome Type
    • Loaded Cargos
      • Peptide
      • siRNA
      • mRNA
      • miRNA
      • Protein
      • Chemical
      • Others
    • Non-cargo
  • Cell Source
    • HEK293 Cells
    • MSCs
    • Platelets
    • Erythrocytes
    • Natural Killer Cells
    • Others
  • Application
    • Therapeutics
      • Oncology
      • Neurodegenerative Diseases
      • Cardiovascular Diseases
      • Infectious Diseases
      • Cosmetics
      • Others
    • Diagnostics
  • End-user
    • Health Care Providers
    • Pharmaceutical & Biotechnology Companies
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • AEGLE Therapeutics
  • Aruna Bio, Inc.
  • Bio-Techne Corporation
  • Carmine Therapeutics, Inc.
  • Codiak BioSciences, Inc.
  • Creative Biolabs
  • Danaher Corporation (Beckman Coulter, Inc.)
  • Fujifilm Holdings Corporation
  • NOVADIP Biosciences S.A.
  • OmniSpirant Limited
  • Thermo Fisher Scientific, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global exosome technologies market in 2022?

The global industry was valued at US$ 47.3 Mn in 2022

How big will the exosome technologies industry be in 2031?

It is projected to reach more than US$ 343.5 Mn by 2031

What will be the CAGR of the exosome technologies business during the forecast period?

It is anticipated to advance at a CAGR of 24.8% from 2023 to 2031

Which are the prominent factors fueling demand for exosome technologies?

Surge in prevalence of chronic diseases, increase in awareness about exosome technologies, and rise in government initiatives to increase funding for research & development are driving the market

Which of the exosome technologies segment accounted for major share in 2022?

The loaded cargos exosome type segment accounted for major share in 2022

Which region is expected to be lucrative for exosome technologies during the forecast period?

North America is expected to be a highly lucrative region from 2023 to 2031

Who are the prominent exosome technologies players?

AEGLE Therapeutics, Aruna Bio, Inc., Bio-Techne Corporation (Exosome Diagnostics, Inc.), Carmine Therapeutics, Inc., Codiak BioSciences, Inc., Creative Biolabs, Danaher Corporation (Beckman Coulter, Inc.), Fujifilm Holdings Corporation, NOVADIP Biosciences S.A., OmniSpirant Limited, and Thermo Fisher Scientific, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Exosome Technologies Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Exosome Type Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Exosome Technologies Market Analysis and Forecasts, 2017 - 2031

            4.4.1. Market Revenue Projections (US$ Mn)

            4.4.2. Market Volume/Unit Shipments Projections

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Technological Advancements

        5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

    6. Global Exosome Technologies Market Analysis and Forecasts, by Exosome Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Exosome Type, 2017 - 2031

            6.3.1. Loaded Cargos

                6.3.1.1. Peptide

                6.3.1.2. siRNA

                6.3.1.3. mRNA

                6.3.1.4. miRNA

                6.3.1.5. Protein

                6.3.1.6. Chemical

                6.3.1.7. Others

            6.3.2. Non-cargo

        6.4. Market Attractiveness By Exosome Type

    7. Global Exosome Technologies Market Analysis and Forecasts, by Cell Source

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Cell Source, 2017 - 2031

            7.3.1. HEK293 Cells

            7.3.2. MSCs

            7.3.3. Platelets

            7.3.4. Erythrocytes

            7.3.5. Natural Killer Cells

            7.3.6. Others

        7.4. Market Attractiveness By Cell Source

    8. Global Exosome Technologies Market Analysis and Forecasts, by Application

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By Application, 2017 - 2031

            8.3.1. Therapeutics

                8.3.1.1. Oncology

                8.3.1.2. Neurodegenerative Diseases

                8.3.1.3. Cardiovascular Diseases

                8.3.1.4. Infectious Diseases

                8.3.1.5. Cosmetics

            8.3.2. Diagnostics

        8.4. Market Attractiveness By Application

    9. Global Exosome Technologies Market Analysis and Forecasts, by End-user

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast By End-user, 2017 - 2031

            9.3.1. Health Care Providers

            9.3.2. Pharmaceutical & Biotechnology Companies

            9.3.3. Others

        9.4. Market Attractiveness By End-user

    10. Global Exosome Technologies Market Analysis and Forecasts, by Region

        10.1. Key Findings

        10.2. Market Value Forecast By Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness By Country/Region

    11. North America Exosome Technologies Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Exosome Type, 2017 - 2031

            11.2.1. Loaded Cargos

                11.2.1.1. Peptide

                11.2.1.2. siRNA

                11.2.1.3. mRNA

                11.2.1.4. miRNA

                11.2.1.5. Protein

                11.2.1.6. Chemical

                11.2.1.7. Others

            11.2.2. Non-cargo

        11.3. Market Value Forecast By Cell Source, 2017 - 2031

            11.3.1. HEK293 Cells

            11.3.2. MSCs

            11.3.3. Platelets

            11.3.4. Erythrocytes

            11.3.5. Natural Killer Cells

            11.3.6. Others

        11.4. Market Value Forecast By Application, 2017 - 2031

            11.4.1. Therapeutics

                11.4.1.1. Oncology

                11.4.1.2. Neurodegenerative Diseases

                11.4.1.3. Cardiovascular Diseases

                11.4.1.4. Infectious Diseases

                11.4.1.5. Cosmetics

            11.4.2. Diagnostics

        11.5. Market Value Forecast By End-user, 2017 - 2031

            11.5.1. Health Care Providers

            11.5.2. Pharmaceutical & Biotechnology Companies

            11.5.3. Others

        11.6. Market Value Forecast By Country, 2017 - 2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Exosome Type

            11.7.2. By Cell Source

            11.7.3. By Application

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Exosome Technologies Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Exosome Type, 2017 - 2031

            12.2.1. Loaded Cargos

                12.2.1.1. Peptide

                12.2.1.2. siRNA

                12.2.1.3. mRNA

                12.2.1.4. miRNA

                12.2.1.5. Protein

                12.2.1.6. Chemical

                12.2.1.7. Others

            12.2.2. Non-cargo

        12.3. Market Value Forecast By Cell Source, 2017 - 2031

            12.3.1. HEK293 Cells

            12.3.2. MSCs

            12.3.3. Platelets

            12.3.4. Erythrocytes

            12.3.5. Natural Killer Cells

            12.3.6. Others

        12.4. Market Value Forecast By Application, 2017 - 2031

            12.4.1. Therapeutics

                12.4.1.1. Oncology

                12.4.1.2. Neurodegenerative Diseases

                12.4.1.3. Cardiovascular Diseases

                12.4.1.4. Infectious Diseases

                12.4.1.5. Cosmetics

            12.4.2. Diagnostics

        12.5. Market Value Forecast By End-user, 2017 - 2031

            12.5.1. Health Care Providers

            12.5.2. Pharmaceutical & Biotechnology Companies

            12.5.3. Others

        12.6. Market Value Forecast By Country, 2017 - 2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Exosome Type

            12.7.2. By Cell Source

            12.7.3. By Application

            12.7.4. By End-user

            12.7.5. By Country

    13. Asia Pacific Exosome Technologies Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Exosome Type, 2017 - 2031

            13.2.1. Loaded Cargos

                13.2.1.1. Peptide

                13.2.1.2. siRNA

                13.2.1.3. mRNA

                13.2.1.4. miRNA

                13.2.1.5. Protein

                13.2.1.6. Chemical

                13.2.1.7. Others

            13.2.2. Non-cargo

        13.3. Market Value Forecast By Cell Source, 2017 - 2031

            13.3.1. HEK293 Cells

            13.3.2. MSCs

            13.3.3. Platelets

            13.3.4. Erythrocytes

            13.3.5. Natural Killer Cells

            13.3.6. Others

        13.4. Market Value Forecast By Application, 2017 - 2031

            13.4.1. Therapeutics

                13.4.1.1. Oncology

                13.4.1.2. Neurodegenerative Diseases

                13.4.1.3. Cardiovascular Diseases

                13.4.1.4. Infectious Diseases

                13.4.1.5. Cosmetics

            13.4.2. Diagnostics

        13.5. Market Value Forecast By End-user, 2017 - 2031

            13.5.1. Health Care Providers

            13.5.2. Pharmaceutical & Biotechnology Companies

            13.5.3. Others

        13.6. Market Value Forecast By Country, 2017 - 2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Exosome Type

            13.7.2. By Cell Source

            13.7.3. By Application

            13.7.4. By End-user

            13.7.5. By Country

    14. Latin America Exosome Technologies Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Exosome Type, 2017 - 2031

            14.2.1. Loaded Cargos

                14.2.1.1. Peptide

                14.2.1.2. siRNA

                14.2.1.3. mRNA

                14.2.1.4. miRNA

                14.2.1.5. Protein

                14.2.1.6. Chemical

                14.2.1.7. Others

            14.2.2. Non-cargo

        14.3. Market Value Forecast By Cell Source, 2017 - 2031

            14.3.1. HEK293 Cells

            14.3.2. MSCs

            14.3.3. Platelets

            14.3.4. Erythrocytes

            14.3.5. Natural Killer Cells

            14.3.6. Others

        14.4. Market Value Forecast By Application, 2017 - 2031

            14.4.1. Therapeutics

                14.4.1.1. Oncology

                14.4.1.2. Neurodegenerative Diseases

                14.4.1.3. Cardiovascular Diseases

                14.4.1.4. Infectious Diseases

                14.4.1.5. Cosmetics

            14.4.2. Diagnostics

        14.5. Market Value Forecast By End-user, 2017 - 2031

            14.5.1. Health Care Providers

            14.5.2. Pharmaceutical & Biotechnology Companies

            14.5.3. Others

        14.6. Market Value Forecast By Country, 2017 - 2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Exosome Type

            14.7.2. By Cell Source

            14.7.3. By Application

            14.7.4. By End-user

            14.7.5. By Country

    15. Middle East & Africa Exosome Technologies Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast By Exosome Type, 2017 - 2031

            15.2.1. Loaded Cargos

                15.2.1.1. Peptide

                15.2.1.2. siRNA

                15.2.1.3. mRNA

                15.2.1.4. miRNA

                15.2.1.5. Protein

                15.2.1.6. Chemical

                15.2.1.7. Others

            15.2.2. Non-cargo

        15.3. Market Value Forecast By Cell Source, 2017 - 2031

            15.3.1. HEK293 Cells

            15.3.2. MSCs

            15.3.3. Platelets

            15.3.4. Erythrocytes

            15.3.5. Natural Killer Cells

            15.3.6. Others

        15.4. Market Value Forecast By Application, 2017 - 2031

            15.4.1. Therapeutics

                15.4.1.1. Oncology

                15.4.1.2. Neurodegenerative Diseases

                15.4.1.3. Cardiovascular Diseases

                15.4.1.4. Infectious Diseases

                15.4.1.5. Cosmetics

            15.4.2. Diagnostics

        15.5. Market Value Forecast By End-user, 2017 - 2031

            15.5.1. Health Care Providers

            15.5.2. Pharmaceutical & Biotechnology Companies

            15.5.3. Others

        15.6. Market Value Forecast By Country, 2017 - 2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Exosome Type

            15.7.2. By Cell Source

            15.7.3. By Application

            15.7.4. By End-user

            15.7.5. By Country

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (By Tier and Size of companies)

        16.2. Market Share Analysis By Company (2021)

        16.3. Company Profiles

            16.3.1. AEGLE Therapeutics

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Test Type Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Aruna Bio, Inc.

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Test Type Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. Bio-Techne Corporation (Exosome Diagnostics, Inc.)

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Test Type Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. Carmine Therapeutics, Inc.

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Test Type Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Codiak BioSciences, Inc.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Test Type Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. Creative Biolabs

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Test Type Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. Danaher Corporation (Beckman Coulter, Inc.)

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Test Type Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Fujifilm Holdings Corporation

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Test Type Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. NOVADIP Biosciences S.A.

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Test Type Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

            16.3.10. OmniSpirant Limited

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Test Type Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

                16.3.10.5. Strategic Overview

            16.3.11. Thermo Fisher Scientific, Inc.

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Test Type Portfolio

                16.3.11.3. Financial Overview

                16.3.11.4. SWOT Analysis

                16.3.11.5. Strategic Overview

    List of Tables

    Table 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

    Table 02: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

    Table 03: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

    Table 04: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 05: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 06: Global Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 07: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 08: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 09: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

    Table 10: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

    Table 11: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

    Table 12: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 13: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 14: North America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 15: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 16: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

    Table 17: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

    Table 18: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

    Table 19: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 20: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 21: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 22: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 23: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

    Table 24: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

    Table 25: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

    Table 26: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 27: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 28: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 29: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 30: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

    Table 31: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

    Table 32: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

    Table 33: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 34: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 35: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 36: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 37: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

    Table 38: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

    Table 39: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

    Table 40: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 41: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

    Table 42: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    List of Figures

    Figure 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: Global Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031

    Figure 03: Global Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031

    Figure 04: Global Exosome Technologies Market (US$ Mn), by Loaded Cargos, 2017-2031

    Figure 05: Global Exosome Technologies Market (US$ Mn), by Non-cargo, 2017-2031

    Figure 06: Global Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031

    Figure 07: Global Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031

    Figure 08: Global Exosome Technologies Market (US$ Mn), by HEK293 Cells, 2017-2031

    Figure 09 Global Exosome Technologies Market (US$ Mn), by MSCs, 2017-2031

    Figure 10: Global Exosome Technologies Market (US$ Mn), by Platelets, 2017-2031

    Figure 11: Global Exosome Technologies Market (US$ Mn), by Erythrocytes, 2017-2031

    Figure 12: Global Exosome Technologies Market (US$ Mn), by Natural Killer Cells, 2017-2031

    Figure 13: Global Exosome Technologies Market (US$ Mn), by Others, 2017-2031

    Figure 14: Global Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031

    Figure 15: Global Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031

    Figure 16: Global Exosome Technologies Market (US$ Mn), by Therapeutics, 2017-2031

    Figure 17: Global Exosome Technologies Market (US$ Mn), by Diagnostics, 2017-2031

    Figure 18: Global Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 19: Global Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 20: Global Exosome Technologies Market (US$ Mn), by Health Care Providers, 2017-2031

    Figure 21: Global Exosome Technologies Market (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031

    Figure 22: Global Exosome Technologies Market (US$ Mn), by Others, 2017-2031

    Figure 23: Global Exosome Technologies Market Value Share Analysis, by Region, 2022 and 2031

    Figure 24: Global Exosome Technologies Market Attractiveness Analysis, by Region, 2023-2031

    Figure 25: North America Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031

    Figure 26: North America Exosome Technologies Market Value Share Analysis, by Country, 2022 and 2031

    Figure 27: North America Exosome Technologies Market Attractiveness Analysis, by Country, 2023-2031

    Figure 28: North America Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031

    Figure 29: North America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031

    Figure 30: North America Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031

    Figure 31: North America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031

    Figure 32: North America Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031

    Figure 33: North America Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031

    Figure 34: North America Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 35: North America Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 36: Europe Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031

    Figure 37: Europe Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 38: Europe Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 39: Europe Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031

    Figure 40: Europe Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031

    Figure 41: Europe Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031

    Figure 42: Europe Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031

    Figure 43: Europe Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031

    Figure 44: Europe Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031

    Figure 45: Europe Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 46: Europe Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 47: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031

    Figure 48: Asia Pacific Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 49: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 50: Asia Pacific Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031

    Figure 51: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031

    Figure 52: Asia Pacific Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031

    Figure 53: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031

    Figure 54: Asia Pacific Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031

    Figure 55: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031

    Figure 56: Asia Pacific Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 57: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 58: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031

    Figure 59: Latin America Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 60: Latin America Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 61: Latin America Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031

    Figure 62: Latin America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031

    Figure 63: Latin America Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031

    Figure 64: Latin America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031

    Figure 65: Latin America Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031

    Figure 66: Latin America Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031

    Figure 67: Latin America Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 68: Latin America Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 69: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031

    Figure 70: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 71: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 72: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031

    Figure 73: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031

    Figure 74: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031

    Figure 75: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031

    Figure 76: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031

    Figure 77: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031

    Figure 78: Middle East & Africa Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 79: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 80: Global Exosome Technologies Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved